Ibrutinib treatment ameliorates murine chronic graft-versus-host disease

Jason A. Dubovsky, … , John C. Byrd, Bruce R. Blazar

*J Clin Invest.* 2014;124(11):4867-4876. [https://doi.org/10.1172/JCI75328](https://doi.org/10.1172/JCI75328).

Chronic graft-versus-host disease (cGVHD) is a life-threatening impediment to allogeneic hematopoietic stem cell transplantation, and current therapies do not completely prevent and/or treat cGVHD. CD4+ T cells and B cells mediate cGVHD; therefore, targeting these populations may inhibit cGVHD pathogenesis. Ibrutinib is an FDA-approved irreversible inhibitor of Bruton’s tyrosine kinase (BTK) and IL-2 inducible T cell kinase (ITK) that targets Th2 cells and B cells and produces durable remissions in B cell malignancies with minimal toxicity. Here, we evaluated whether ibrutinib could reverse established cGVHD in 2 complementary murine models, a model interrogating T cell–driven sclerodermatous cGVHD and an alloantibody-driven multiorgan system cGVHD model that induces bronchiolar obliterans (BO). In the T cell–mediated sclerodermatous cGVHD model, ibrutinib treatment delayed progression, improved survival, and ameliorated clinical and pathological manifestations. In the alloantibody-driven cGVHD model, ibrutinib treatment restored pulmonary function and reduced germinal center reactions and tissue immunoglobulin deposition. Animals lacking BTK and ITK did not develop cGVHD, indicating that these molecules are critical to cGVHD development. Furthermore, ibrutinib treatment reduced activation of T and B cells from patients with active cGVHD. Our data demonstrate that B cells and T cells drive cGVHD and suggest that ibrutinib has potential as a therapeutic agent, warranting consideration for cGVHD clinical trials.

Find the latest version:

http://jci.me/75328-pdf
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease


Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA. Masonic Cancer Center and Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota, USA. College of Veterinary Medicine, Veterinary and Comparative Medicine, The Ohio State University, Columbus, Ohio, USA. Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA. Department of Dermatology, University of California–Davis Cancer Center and School of Medicine, Sacramento, California, USA. Department of Pediatrics, School of Medicine, Medical College of Georgia, Augusta, Georgia, USA. Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Queensland Institute of Medical Research Berghofer Medical Research Institute, Brisbane, Queensland, Australia. Life Sciences Institute, University of Michigan, Ann Arbor, Michigan, USA. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Pharmacyclics Inc., Sunnyvale, California, USA.

Chronic graft-versus-host disease (cGVHD) is a life-threatening impediment to allogeneic hematopoietic stem cell transplantation, and current therapies do not completely prevent and/or treat cGVHD. CD4+ T cells and B cells mediate cGVHD; therefore, targeting these populations may inhibit cGVHD pathogenesis. Ibrutinib is an FDA-approved irreversible inhibitor of Bruton’s tyrosine kinase (BTK) and IL-2 inducible T cell kinase (ITK) that targets Th2 cells and B cells and produces durable remissions in B cell malignancies with minimal toxicity. Here, we evaluated whether ibrutinib could reverse established cGVHD in 2 complementary murine models, a model interrogating T cell–driven sclerodermatous cGVHD and an alloantibody-driven multiorgan system cGVHD model that induces bronchiolar obliterans (BO). In the T cell–mediated sclerodermatous cGVHD model, ibrutinib treatment delayed progression, improved survival, and ameliorated clinical and pathological manifestations. In the alloantibody-driven cGVHD model, ibrutinib treatment restored pulmonary function and reduced germinal center reactions and tissue immunoglobulin deposition. Animals lacking BTK and ITK did not develop cGVHD, indicating that these molecules are critical to cGVHD development. Furthermore, ibrutinib treatment reduced activation of T and B cells from patients with active cGVHD. Our data demonstrate that B cells and T cells drive cGVHD and suggest that ibrutinib has potential as a therapeutic agent, warranting consideration for cGVHD clinical trials.

Introduction

Chronic graft-versus-host disease (cGVHD) is a primary cause of nonrelapse mortality after allogeneic hematopoietic stem cell transplantation (HSCT) (1–4). Drug therapy for cGVHD has been predominantly limited to steroids and calcineurin inhibitors, which are incompletely effective and associated with infections as well as long-term risks of toxicity (5). Novel therapeutics that pinpoint pathogenic immune subsets might control cGVHD yet preserve immune effector functions.

In contrast to acute GVHD, cGVHD is a relatively acellular process that has fibrosis as a dominant feature. The specific immune phenomena that underlie cGVHD are variable; however, recent studies show that B cells, in addition to specific CD4+ T cell subsets, are key mediators of cGVHD (6–8). It has been demonstrated that pathogenic antibody deposition occurs in human cGVHD (9–12). A network of alloreactive T helper cells, including Th1, Th2, Th17, and T follicular helper (Tfh) cells, infiltrate tissues and produce a milieu of effector cytokines resulting in antibody deposition, tissue fibrosis, and autoimmunity (6, 8, 13–15).

Many of the cellular activation and effector functions of these lymphoid subsets can be molecularly tethered to Bruton’s tyrosine kinase (BTK) and IL-2 inducible T cell kinase (ITK) (16, 17). BTK and ITK are highly conserved Tec family kinases that propagate immune receptor-based signaling in B and T lymphocytes, respectively (16). These molecules are activated upstream by SRC family kinases and, upon autophosphorylation, drive downstream acti-
The Journal of Clinical Investigation

RESEARCH ARTICLE

The Journal of Clinical Investigation

ReseaR ch aR ticle

4868

jci.org   Volume 124   Number 11   November 2014

The Journal of Clinical Investigation

ReseaR ch aR ticle

4868

jci.org   Volume 124   Number 11   November 2014

The Journal of Clinical Investigation

ReseaR ch aR ticle

4868

jci.org   Volume 124   Number 11   November 2014

The Journal of Clinical Investigation

ReseaR ch aR ticle

4868

jci.org   Volume 124   Number 11   November 2014

The Journal of Clinical Investigation

ReseaR ch aR ticle

4868

jci.org   Volume 124   Number 11   November 2014

The Journal of Clinical Investigation

ReseaR ch aR ticle

4868

jci.org   Volume 124   Number 11   November 2014

The Journal of Clinical Investigation

ReseaR ch aR ticle

4868

jci.org   Volume 124   Number 11   November 2014

Model, which develops bronchiolar obliterans (BO) syndrome and multiorgan cGVHD without skin involvement (7, 33). In this model, ibrutinib blocked germinal center (GC) formation and Ig deposition, reduced tissue fibrosis, and reversed BO-associated pulmonary dysfunction. Genetic studies confirmed that ITK and BTK are independently critical for the development of cGVHD. These data strongly support the clinical investigation of ibrutinib as a novel therapeutic strategy for the treatment of cGVHD.

Results

Therapeutic administration of ibrutinib limits the development of sclerodermatous lesions in a murine cGVHD model. To assess the efficacy of ibrutinib as a therapeutic intervention for cGVHD, we used the LP/J→C57BL/6 model of sclerodermatous cGVHD, which develops dermal lesions characterized by hair loss, redness, flaking, scabbing, hunched posture, and thickened skin (32). In this murine model, symptoms become apparent between days 20 and 25 and peak between days 37 and 47 after HSCT. Ibrutinib or vehicle treatment was initiated in randomized cohorts at day 25, after the initial clinical signs of cGVHD (weight loss, hair loss, skin redness/flaking, hunched posture, or immobility) were visible in the majority (72%) of mice. Upon inspection at day 39 (14 days after starting therapy), ibrutinib-treated mice clearly lacked the sclerodermatous lesions, hair loss, hunched posture, and scabbing that were observed in both the vehicle and cyclosporine treatment groups (Figure 1A). The development of cGVHD in this model was not effectively constrained by 10 mg/kg/d cyclosporine therapy that is T cell immune suppressive (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI75328DS1). Histology of representative skin lesions obtained

vation of NF-κB, MAPK, and nuclear factor of activated T cells (NFAT) in lymphocytes, resulting in cellular activation, release of soluble effector molecules, and rapid proliferation (18). Antibody production by B cells hinges upon the function of BTK (17). Whereas Th1, Treg, and CD8+ effector T cells have both ITK and resting lymphocyte kinase (RLK, aka TXK) to drive activation, epigenetic evolution of Th2 and Th17 cells conserves a singular dominant role for ITK (19–24). This TEC-kinase profile difference provides an avenue to selectively target T cell subsets potentially highly relevant to cGVHD. However, to date, the individual impact of BTK or ITK on the development of cGVHD is unknown.

Ibrutinib is a first-in-class irreversible inhibitor of BTK and ITK that blocks downstream immune receptor activation (25–27). Numerous in vitro and in vivo studies confirm the specific activity and clinical safety of ibrutinib for the treatment of specific TEC-kinase–dependent malignancies (28–31). Since ibrutinib can block the activation of B cells via BTK inhibition as well as specific T helper subsets that drive the development of cGVHD via ITK inhibition, we hypothesized that it may be ideally suited to the treatment of cGVHD.

To study the multifaceted effects of this inhibitor in vivo and interrogate the activity of both T and B cells in the development of multiorgan systemic cGVHD, we used 2 complementary murine allogeneic HSCT models representing sclerodermatous and non-sclerodermatous cGVHD manifestations. Here, we show that ibrutinib treatment ameliorates the progression of cGVHD in the LP/J→C57BL/6 T cell–dependent murine model of scleroderma
tous cGVHD, reducing skin lesions, hair loss, and lymphohistiocytic infiltration (32). Therapeutic administration of ibrutinib also proved effective at combating cGVHD in the C57BL/6→B10.BR model, which develops bronchiolar obliterans (BO) syndrome and multiorgan cGVHD without skin involvement (7, 33). In this model, ibrutinib blocked germinal center (GC) formation and Ig deposition, reduced tissue fibrosis, and reversed BO-associated pulmonary dysfunction. Genetic studies confirmed that ITK and BTK are independently critical for the development of cGVHD. These data strongly support the clinical investigation of ibrutinib as a novel therapeutic strategy for the treatment of cGVHD.

Figure 1. Scleroderma and skin manifestations of cGVHD are alleviated by ibrutinib therapy. At day 25 after HSCT, a total of 18 mice (from 2 independent experiments) were randomly assigned to ibrutinib (25 mg/kg/d), 18 to vehicle, and 11 to cyclosporine (10 mg/kg/d). Sclerodermatous lesions, hair loss, hunched posture, and gaunt appearance are characteristic visual indicators of cGVHD in this model. (A) Representative visual analysis of 4 randomly selected mice at day 39 after HSCT. (B) H&E-stained skin preparations of sclerodermatous skin lesions showing levels of dermal fibrosis, epidermal hyperplasia, serocellular crusting, erosion, and lymphohistiocytic infiltration, consistent with cGVHD. Original magnification, ×200. (C) Pathologic cGVHD involvement of the skin was independently assessed on a scale from 0 to 8 for each mouse. Cohort averages are displayed. *P < 0.05. Error bars indicate SEM.
sections revealed that, compared with vehicle controls, ibrutinib
E-stained
generations that are infrequently observed. Evaluation of H
ops pulmonary and renal cGVHD among other cGVHD patholo-
C57BL/6 model consistently devel-
→
demonstrated that the LP /J
ure 6). Weekly evaluation of mouse body weights revealed little
progression free compared with 12% (2 of 18) receiving vehicle
days; moreover, 33% (6 of 18) of ibrutinib-treated mice remained
significantly extended median time to cGVHD progression by 14
derived from 2 independent experiments show that ibrutinib sig-
score from the initiation of therapy (Supplemental Table 1). Data
vehicle treatment (ibrutinib = 1.5, vehicle = 1, cyclosporine = 2.9 of a possible 19).
Using these metrics, we found that mice treated with ibrutinib sig-
(ibrutinib = 1.5, vehicle = 1, cyclosporine = 2.9 of a possible 19).
Using these metrics, we found that mice treated with ibrutinib sig-
ificantly reduced the overall intensity of cGVHD compared with
vehicle treatment (P = 0.0184) (Figure 2A, Supplemental Table 1, and Supplemental Figure 4). Chronic GVHD progression in this
model is defined as a greater than 2-point increase in cGVHD
score, which was not observed by external cGVHD scoring (Supplemental Figure 11).
Coded pathologic analysis con-
irmed that ibrutinib improved systemic cGVHD in this model
(P = 0.0099 for lung and P = 0.0124 for kidney) (Figure 3, B and C, and Supplemental Figures 9 and 10).

Maximum ibrutinib therapeutic benefit in scleroderma
tous cGVHD requires prolonged administration. To understand the sustained
therapeutic benefits of ibrutinib and the potential consequences of
drug withdrawal, we conducted an additional long-term thera-
peutic experiment (Figure 3D). Once again, ibrutinib significantly
limited cGVHD progression as compared with vehicle control
(P = 0.0019). We also found that withdrawal of therapy at day 60
 permitted clinical breakthrough cGVHD in a single mouse (1 of 6);
however, this was not statistically significant. A similar trend was
observed by external cGVHD scoring (Supplemental Figure 11).
Analysis of internal cGVHD pathology within the pulmonary and
renal tissues on day 75 suggested that continuous long-term ibrut-
inib was more effective at controlling cGVHD; notably, internal
pathology of the lung and kidney was not curtailed in BM-only
recipients, indicating that certain cGVHD internal pathology in
this model persists despite the elimination of T cells from the graft
similar to what is observed in human allo-HSCT recipients (Sup-
plemental Figure 12, A and B). Prophylactic ibrutinib treatment
initiated pre-HSCT at day –2 and concluded at day 25 did not yield
a significant improvement in cGVHD progression (Supplemental
Figure 13), suggesting that ibrutinib will be most effective when T
and B cell responses are more fully developed.

Therapeutic administration of ibrutinib ameliorates pulmonary
fibrosis and the development of BO. cGVHD is characterized by a wide
variety of autoimmune manifestations that are incompletely reca-
pitulated by any single in vivo animal model. Recently published
consensus criterion from the NIH considers BO the only pathogno-
monic manifestation of lung cGVHD (35). The C57BL/6→B10.BR

at day 60 from vehicle- or cyclosporine-treated mice confirmed
dermal fibrosis, epidermal hyperplasia, serocellular crusting, ero-
sion, and lymphohistiocytic infiltration, which were not observed
in skin samples from the ibrutinib-treated group (Figure 1, B and
C, and Supplemental Figures 2 and 3).

Ibrutinib improves scleroderma
tous cGVHD progression-free
survival and diminishes clinical and histopathological evidence of
cGVHD. To define cGVHD severity and progression in the LP/J→
C57BL/6 model, we used a scoring system that quantitatively
grades cGVHD metrics including the following: body weight, post-
ture, mobility, hair loss, skin lesions, and vitality on a scale from
0 to 19 by a consistent and trained unbiased observer in a coded
(blinded) manner (Supplemental Table 1 and ref. 34). Overall, 72%
of mice (34 of 47) had active cGVHD on day 25, and the randomly
assigned cohorts were very similar in initial (day 25) cGVHD score
(ibrutinib = 1.5, vehicle = 1, cyclosporine = 2.9 of a possible 19).
Using these metrics, we found that mice treated with ibrutinib sig-
ificantly reduced the overall intensity of cGVHD compared with
vehicle treatment (P = 0.0184) (Figure 2A, Supplemental Table 1, and Supplemental Figure 4). Chronic GVHD progression in this
model is defined as a greater than 2-point increase in cGVHD
score, which was not observed by external cGVHD scoring (Supplemental Figure 11).
Coded pathologic analysis con-
irmed that ibrutinib improved systemic cGVHD in this model
(P = 0.0099 for lung and P = 0.0124 for kidney) (Figure 3, B and C, and Supplemental Figures 9 and 10).
Maximum ibrutinib therapeutic benefit in scleroderma
tous cGVHD requires prolonged administration. To understand the sustained
therapeutic benefits of ibrutinib and the potential consequences of
drug withdrawal, we conducted an additional long-term thera-
peutic experiment (Figure 3D). Once again, ibrutinib significantly
limited cGVHD progression as compared with vehicle control
(P = 0.0019). We also found that withdrawal of therapy at day 60
 permitted clinical breakthrough cGVHD in a single mouse (1 of 6);
however, this was not statistically significant. A similar trend was
observed by external cGVHD scoring (Supplemental Figure 11).
Analysis of internal cGVHD pathology within the pulmonary and
renal tissues on day 75 suggested that continuous long-term ibrut-
inib was more effective at controlling cGVHD; notably, internal
pathology of the lung and kidney was not curtailed in BM-only
recipients, indicating that certain cGVHD internal pathology in
this model persists despite the elimination of T cells from the graft
similar to what is observed in human allo-HSCT recipients (Sup-
plemental Figure 12, A and B). Prophylactic ibrutinib treatment
initiated pre-HSCT at day –2 and concluded at day 25 did not yield
a significant improvement in cGVHD progression (Supplemental
Figure 13), suggesting that ibrutinib will be most effective when T
and B cell responses are more fully developed.

Therapeutic administration of ibrutinib ameliorates pulmonary
fibrosis and the development of BO. cGVHD is characterized by a wide
variety of autoimmune manifestations that are incompletely reca-
pitulated by any single in vivo animal model. Recently published
consensus criterion from the NIH considers BO the only pathogno-
monic manifestation of lung cGVHD (35). The C57BL/6→B10.BR

Figure 2. Ibrutinib inhibits autoimmune manifestations of cGVHD. (A) Weekly blinded analysis of cGVHD external metrics including weight, posture, vitality, mobility, coat, and skin in all mice from 2 independent experiments (18 vehicle and 18 ibrutinib) (Supplemental Table 1). All cGVHD scores were corrected for individual scores at the beginning of treatment (day 25). Error bars indicate SEM. *P < 0.01. (B) Kaplan-Meier plot of cGVHD progress-
→
ion–free survival. Data are derived from 2 independent experiments. Progression is defined as a greater than 2-point increase in day 25 cGVHD score
(Supplemental Table 1) *P < 0.01.
Ibrutinib limits in vivo GC reactions and Ig deposition in pulmonary tissues. Ibrutinib’s ability to block B cell receptor–induced (BCR-induced) activation of BTK is well defined; however, it remains unclear whether GC reactions are effectively inhibited. To study this, we utilized the C57BL/6→B10.BR mouse model in which robust GC reactions sustain pathogenic B lymphocytes and lead to Ig deposition within the liver and lungs and the development of BO. Peanut agglutinin staining revealed GC reactions within the spleen, and ibrutinib therapy reduced the overall size, cellularity, and number of GC reactions compared with those of vehicle-treated mice with active cGVHD ($P < 0.001$) (Figure 5, A and B). On day 60 after HSCT, isolated splenocytes from chimeras were analyzed by flow cytometry for CD19$^+$GL7$^+$CD38$^{lo}$ GC cells. TheJournal of Clinical Investigation

**Figure 5.** Ibrutinib therapy reduces pulmonary inflammation. (A) Representative images from H&E-, B220-, or CD3-stained lung and kidney tissues from mice sacrificed at day 125 after HSCT from 6 mice/group. Images were taken by a trained veterinary pathologist who was blinded to animal cohorts. Original magnification, ×200. (B) Blinded pathologic analysis of H&E-stained lung tissues obtained from cGVHD cohorts (18 vehicle and 18 ibrutinib). Lymphohistiocytic infiltration was graded on a 0 to 4 scale for each animal. (C) Blinded pathologic analysis of H&E-stained kidney tissues obtained from cGVHD cohorts. Portal hepatitis and vasculitis were graded on a 0 to 4 scale for each animal. *$P < 0.05$; **$P < 0.01$. (D) Kaplan-Meier plot of cGVHD progression-free survival in an independent experiment aimed to determine sustained benefits from continued ibrutinib therapy. During the course of the experiment, ibrutinib was withdrawn on day 60 from animals in the Ibrutinib (day 25 to day 60) cohort. **$P < 0.001$. 

Ibrutinib therapy reduces BO development. Day –2 to day 28 prophylactic administration of ibrutinib in this model also did not effectively combat cGVHD or BO (data not shown). Overall, these data indicate that ibrutinib therapy reduces the underlying fibrotic pathogenesis of BO in the C57BL/6→B10.BR cGVHD model.

The model develops multiorgan system disease including BO starting at day 28 after HSCT. Therapeutic administration of ibrutinib beginning at day 28 and continuing indefinitely curtailed the development of BO in vivo as measured by pulmonary resistance ($P = 0.0090$), elastance ($P = 0.0019$), and compliance ($P = 0.0071$) (Figure 4A–C). Masson trichrome staining of inflated pulmonary tissues from 4 mice derived from 3 experiments revealed less peribroncholeolar collagen fibrosis among ibrutinib-treated animals (Figure 4D) and a significant reduction in pulmonary fibrosis ($P < 0.0001$) (Figure 4E). We observed 100% survival in the ibrutinib cohort versus 95% in the vehicle group (Supplemental Figure 14).
Chronic GVHD sustaining T cells in this model originate from mature lymphocytes in the donor cell graft. To recapitulate the effect of ITK inhibition within these cGVHD-causative T lymphocytes, we administered \textit{Itk}–/– splenic T cells along with BM from WT mice to allogeneic recipients. Day 60 PFTs including resistance, elastance, and compliance were uniformly and significantly (\(P = 0.0014; P = 0.0028; P = 0.0003\)) reduced in mice receiving \textit{Itk}–/– versus WT splenic T cells and comparable to non-cGVHD, BM-only controls (Figure 6). These data reveal that T cell ITK activity is necessary for the development of cGVHD.

Data from both models implicates hyperreactive BTK in B cells isolated from both cGVHD models (Supplemental Figure 17). To genetically confirm the role of BTK signaling in cGVHD, we infused XID BM along with WT splenic T cells to mimic BTK inhibition. PFTs conducted at day 60 after HSCT revealed that BTK activity was essential to the development of BO (Figure 7). Pulmonary resistance, elastance, and compliance were significantly reduced in recipients of WT T cells and XID versus WT BM (\(P = 0.0025; P = 0.0025; P = 0.0496\)) and comparable to XID or WT BM-only controls.

Ibrutinib blocks T and B cell activation in samples obtained from patients with active cGVHD. Our data confirm that BTK and ITK are critical to the development of cGVHD and that ibrutinib works to alleviate the symptoms associated with severe cGVHD in murine models. To confirm that this effect is not restricted to mouse models, we tested the effects of ibrutinib on CD4 T and B cells. Ibrutinib significantly inhibited the cGVHD-induced formation of GCs within the spleen (\(P = 0.0222\)) to numbers comparable to those in the no cGVHD, BM only control (Figure 5C).

The functional product of alloreactive GC B cells is secreted Ig, which deposits within healthy tissues. In the C57BL/6→B10.BR cGVHD model, BO is inextricably related to the deposition of soluble Ig within pulmonary tissues and the fibrotic cascade that this initiates. By blocking B cell reactivity, ibrutinib limited pulmonary deposition of Ig as quantified at day 60 after HSCT using immunofluorescent microscopy (Figure 5D). Quantification of the immunofluorescent signal revealed elimination of pulmonary Ig deposition after therapeutic ibrutinib treatment (\(P < 0.001\)) (Figure 5E). Together, these data confirm that a clinically relevant downstream effect of ibrutinib therapy in the setting of cGVHD is the blockade of Ig deposition within healthy tissues.

Genetic ablation of BTK or ITK activity in allogeneic donor cell engraftment confirms that both TEC kinases are required for the development of cGVHD. The XID mouse in which the kinase activity of BTK is genetically abrogated and the \textit{Itk}–/– mouse have been fully characterized on the C57BL/6 genetic background (36, 37). Given ibrutinib’s ability to inhibit both ITK and BTK, we sought to examine the relative independent contributions of ITK and BTK to the development of cGVHD. We therefore examined pulmonary function at day 60 after HSCT, as this represents a primary functional measurement of cGVHD-induced lung injury and fibrosis in the C57BL/6→B10.BR model.

**Figure 4.** Collagen deposition and pulmonary function are improved in a murine model of bronchiolitis obliterans. (A–C) PFTs were performed at day 60 after transplant on anesthetized animals. Animals (\(n = 4/\text{group}\)) were artificially ventilated and (A) resistance, (B) elastance, and (C) compliance were measured as parameters of distress in lung function in animals receiving \(5 \times 10^6\) splenocytes (S) in addition to BM. Error bars indicate SEM. (D and E) Collagen deposition within pulmonary tissues was determined with a Masson trichrome staining kit; blue indicates collagen deposition. (D) Representative images of collagen deposition observed in each treatment cohort (\(n = 8\)). Blue staining represents Masson trichrome–stained collagen. Original magnification, \(\times 200\). (E) Quantification of collaged deposition (\(n = 8\)) as a ratio of blue area to total area of tissue was performed with the analysis tool in Photoshop CS3. Representative data from 3 independent experiments. *\(P < 0.05\); **\(P < 0.01\); ***\(P < 0.001\).
B cells obtained from patients with active and persistent cGVHD. Data revealed that after pretreatment with 1 μM ibrutinib, CD4+ T cells from these patients demonstrated lower surface expression of CD69 after ex vivo T cell receptor (TCR) stimulation using anti-CD3 (P = 0.033) (Figure 8A). Moreover, purified B cells that were pretreated with 1 μM ibrutinib showed lower levels of pBTK-Y223, pPLCγ2-Y1217, and pERK1/2 by immunoblot analysis (Figure 8B). These data confirm that ibrutinib can curtail immune receptor activation of human B and T cells in the setting of active cGVHD.

Discussion

Chronic GVHD develops from coordinated effects of both B and T cells, and multiple key functions of these cells are driven by TEC family kinases. Here, we show that neither XID BM nor Itk−/− donor T cells facilitate the development of systemic cGVHD in mice, identifying the importance of the TEC kinases BTK and ITK in cGVHD and identifying these 2 enzymes as therapeutic targets in this disease. Therefore, because of its ability to simultaneously target BTK and ITK, ibrutinib holds specific promise for the treatment of cGVHD. Our studies utilize 2 distinct but complementary, validated murine models of cGVHD: one that has dominant scleroderma-tous features and the other with a nonscleroderma-tous, multiorgan system fibrotic disease with BO (32, 33). Our results indicate that ibrutinib targets B and T cell–driven GC responses and is remarkably effective in treating cGVHD. In the sclerodermatous model, animals receiving therapeutic ibrutinib were often indistinguishable from their healthy counterparts, and in the nonsclerodermatous cGVHD model, no cGVHD manifestations were evident even at the end of the observation period. Moreover, GC reaction size, cellularity, and number were lower in mice receiving ibrutinib, correlating to a partial but significant resolution of cGVHD symptoms. These data are consistent with pre-clinical data in which GC reactions are key to cGVHD pathogenesis; for instance, clinical responses to rituximab (anti-CD20 mAb) have been observed, implicating B cells as etiopathogenic in human cGVHD (38–40). Finally, we confirmed that our observation could be applied to human therapy by testing ibrutinib’s capacity to block the molecular activation of T cells and B cells directly obtained from patients with active ongoing cGVHD.

Results from our genetic ablation models reveal that BM-derived B cells depend upon BTK for GC formation. Similarly, Itk−/− splenocytes are unable to cause cGVHD, suggesting that ITK is critical for T cell support of the fibrotic cascade. While XID and Itk−/− mice are useful in exploring the mechanisms responsible for cGVHD generation, there are caveats. For instance, TEC kinase has been shown to compensate for the lack of BTK in the XID mouse model, and complete genetic ablation of ITK blunts thymic maturation of functionally mature T lymphocytes (18, 41, 42). As a result, we can conclude that ITK and BTK are necessary components for the development of cGVHD; however, we cannot
conclude that ibrutinib’s therapeutic efficacy is solely driven by inhibition of these 2 TEC kinases.

In the cGVHD model that has BO as an important feature, fibrosis occurs by day 28 after HSCT. Intriguingly, ibrutinib treatment beginning on day 28 after HSCT in mice with established cGVHD resulted in resolution of fibrosis, suggesting that treatment in the early phase of cGVHD can permit tissue repair and further suggesting that ongoing antibody deposition in cGVHD target organs may be required for a persistent fibrogenic process. Notably, for patients with debilitating cGVHD from fibrosis, therapies include supportive care, high-dose steroids, rapamycin, mycophenolate, imatinib, extracorporeal photopheresis, IL-2, and lung transplant, all with incomplete efficacy and potentially serious complications (43–55).

Although conclusions from rodent cGVHD must be validated in patients, our studies collectively indicate that a wide spectrum of cGVHD patients may benefit from ibrutinib therapy.
The Journal of Clinical Investigation

Research Article

Therapeutic HSCT models. The C57BL/6→B10.BR model has been described previously (7). In brief, B10.BR recipients conditioned with 120 mg/kg/d i.p. cyclophosphamide (Cy) on days –3 and –2 and 8.3 Gy TBI (using a 137Cesium irradiator) on day –1 were engrafted with 1 × 10^7 Thy1.2-depleted C57BL/6 derived BM cells with (or without) 1 × 10^6 allogeneic splenocytes.

Experiments with the LP/J→C57BL/6 model were conducted using methods similar to those previously described (32). Briefly, C57BL/6 recipients were conditioned with 8.5 Gy x-ray TBI on day 0 and were provided 1 × 10^7 LP/J-derived BM cells and 2 × 10^6 splenocytes.

Methods

Mice. C57BL/6 (H2b) mice were purchased from the National Cancer Institute or from The Jackson Laboratory. LP/J and B10.BR (H2k) mice were purchased from The Jackson Laboratory. The C57BL/6 XID mouse, in which a specific mutation abrogates BTK kinase activity, was obtained from The Jackson Laboratory. The C57BL/6 Itk–/– mouse was a gift from Leslie Berg (University of Massachusetts, Boston, Massachusetts, USA) (58). Both strains are maintained on the defined C57BL/6 genetic background (36, 37). All mice were housed in a pathogen-free facility at The Ohio State University or The University of Minnesota.

Figure 7. Expression of BTK in donor-derived B cells is necessary for the development of BO. (A) Day 60 PFTs from mice transplanted with low levels of WT T cells and either WT or XID (kinase inactive BTK) BM. (B) Pathologic scores in lung and (C) liver of day 60 transplanted mice. n = 5 mice/group from 2 independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001.

Figure 8. Ibrutinib limits activation of T cells and B cells from patients with active cGVHD. (A) Primary CD4+ T cells were isolated from patients with active cGVHD, pretreated with 1 μM ibrutinib (or DMSO), and stimulated with anti-CD3 for 6 hours. Graph shows the mean fluorescence intensity (MFI) for CD69 among CD4+ T cells for each patient. *P < 0.05. (B) B cells isolated from patients with cGVHD were pretreated with 1 μM ibrutinib and stimulated with anti-IgM for 45 minutes. Immunoblot analysis of BTK, ERK, and PLCγ2 was conducted. The densitometric quantification of activated proteins relative to total proteins is provided. Data are representative of 3 experiments on 3 separate patients.
cytes by tail-vein injection. Mice surviving to day 25 begin to show clinical and pathological changes consistent with systemic cGVHD, frequently involving the skin, lung, and kidneys and infrequently involving hepatic or salivary gland lymphohistiocytic infiltration, conjunctivitis, anterior uveitis, esophagitis, and corneal ulcers. In our hands, this specific splenocyte and irradiation dose produces a cGVHD phenotype, devoid of the classic gastrointestinal lesions, splenic atrophy, or diarrhea associated with acute GVHD (aGVHD).

The development of cGVHD was measured in coded fashion using a modified version of the scoring system originally described by Cooke et al. (Supplemental Table 1 and ref. 34).

Therapeutic administration of ibrutinib (provided by L. Elias) via drinking water was conducted as previously described (27). Mice received a dose of 15 mg/kg/d ibrutinib in 0.4% methylcellulose by i.p. injection starting at day 28 after transplant for the C57BL/6→B10.BR model or 25 mg/kg/d via drinking water starting at day 25 after transplant for the LP/J→C57BL/6 model. Drinking water administration daily dose was calculated previously (Supplemental Table 2). In the latter strain combination, a cohort of mice was given cyclosporine A administered i.p. in 0.2% CMC at 10 mg/kg/d starting at day 25 for 2 weeks followed by thrice weekly as previously described (59). Unless otherwise stated, ibrutinib was administered until the end of the study.

For both cGVHD models, the BTK pathway was found to be constitutively activated, similar to what has been identified in human cGVHD (Supplemental Figure 17).

PFTs. PFTs were performed on anesthetized mice using whole-body plethysmography with the Flexivent system (SCIREQ) as previously described (7, 33).

GC detection. GC detection was conducted with 6-μm spleen cryosections stained using rhodamine peanut agglutinin as previously described (7).

Masson trichrome staining. Cryosections (6 μM) were fixed for 5 minutes in acetone and stained with H&E and with the Masson Trichrome Staining Kit (Sigma-Aldrich) for detection of collagen deposition. Collagen deposition was quantified on trichrome-stained sections as a ratio of area of blue staining to area of total staining using the Adobe Photoshop CS3 analysis tool.

Histopathological scoring. Coded pathologic analysis of H&E-stained sections was performed by A. Panoskaltsis-Mortari or B.K. Harrington in an unbiased manner with scores ranging from 0 to 4 (60). For pulmonary tissues, scores indicate the number of lymphohistiocytic and histiocytic cellular cuffs infiltrating the surrounding airways or vasculature and the number of infiltrating aggregates. For renal H&E-stained sections, both perivascular lymphohistiocytic infiltration and intratubular protein were quantified. For additional details, see Supplemental Methods.

Immunohistology analysis. Experiments were conducted using conventional methodology previously described (61). Blotting was conducted using pBTK-Y223-, BTK-, pPLCy2-Y1217-, PLCy2-, pERK1/2-, ERK-, and GAPDH-specific antibodies (Cell Signaling Technologies).

Statistics. A 2-tailed Student’s t test was used for normal data at equal variance. Significance was defined as P < 0.05. For cGVHD scoring in the LP/J→C57BL/6 model, a linear mixed effects model was applied to assess the trends in cGVHD scores from days 33 to 52, using the measurement at day 25 as a covariate to account for differences in the initial measurement between treatments. Chronic GVHD progression in the LP/J→C57BL/6 model was prospectively defined as a greater than 2-point increase in cGVHD score from the initiation of therapy (Supplemental Table 1).

Study approval. All animal studies were approved by the institutional animal care committees at The Ohio State University and the University of Minnesota.

Acknowledgments

The authors gratefully acknowledge Leslie J. Berg for providing critical reagents as well as Jessica MacMurray for experimental assistance. This work was supported by grants from the NIH (P01 AI056299, P01 CA142106, R01 HL56067, and R01 AI44995 to B.R. Blazar; T32 AI0107313 to R. Flynn). In addition, support was provided by National Cancer Institute grants (P01 CA095426, K12 CA133250-05, and PS0 CA140158 to J.C. Byrd; T32 CA009338-33-03 to J.A. Dubovsky), as well as grants from the American Cancer Society (125039-PF1-13-246-01-LIB to J.A. Dubovsky), the Leukemia & Lymphoma Society, the American Society of Hematology, Mr. and Mrs. Michael Thomas, the Harry Mangurian Foundation, the D. Warren Brown Family Foundation, and the Jock and Bunny Adams Research and Education Endowment (to J.H. Antin).

Address correspondence to: Bruce R. Blazar, MMC 109, University of Minnesota, Minneapolis, Minnesota 55455, USA. Phone: 612.626.2734; E-mail: blaza001@umn.edu.